JOURNAL OF PHARMA INSIGHTS AND RESEARCH ISSN NO. 3048-5428

REVIEW ARTICLE

Global Regulatory Guidelines and Standards for Drugs Used in Pregnancy

Lokesh A*[1], Magee B[2], Sai Durga Eswari G[2], Sailaja M[2], Rajeswari T[2]

[1] *Assistant Professor, Department of Regulatory Affairs, K.G.R.L College of Pharmacy, Bhimavaram, Andhra Pradesh, India*
[2] *UG Scholar, Department of Regulatory Affairs, K.G.R.L College of Pharmacy, Bhimavaram, Andhra Pradesh, India*

Publication history: Received on 14th December 2025; Revised on 23rd January 2026; Accepted on 25th January 2026

Article DOI: 10.69613/zc5r0r64

Abstract: Pharmacotherapeutic safety during pregnancy requires equilibrium between treating maternal pathology and preventing fetal harm. The historical stringent pharmaceutical oversight catalyzed by the catastrophic outcomes of the Thalidomide tragedy, established a foundational precedent for rigorous preclinical reproductive toxicity assessment. Current global regulatory structures, spearheaded by the U.S. Food and Drug Administration and the European Medicines Agency, prioritize evidence-based narrative summaries over simplified, legacy risk categories. These modern frameworks integrate animal developmental data, placental transfer studies, and available human clinical observations to inform complex prescribing decisions. Physiological adaptations during gestation including expanded plasma volume, altered hepatic enzyme activity, and increased renal filtration profoundly modify drug pharmacokinetics, requiring trimester-specific dosing adjustments to maintain efficacy. Despite these regulatory advances, a persistent "evidence gap" remains due to the ethical complexities of including pregnant populations in controlled clinical trials. Consequently, healthcare providers frequently rely on post-marketing surveillance and voluntary pregnancy exposure registries to identify rare or delayed adverse outcomes. Future improvements in maternal-fetal safety reside in innovative technologies such as placenta-on-a-chip models and physiologically-based pharmacokinetic modeling. Strengthening global harmonization and adopting precision medicine protocols can optimize therapeutic outcomes while minimizing teratogenic risks. A collaborative effort involving active pharmacovigilance and ethical research expansion is vital for the advancement of maternal health without compromising neonatal development.

Keywords: Maternal-Fetal Safety; Pharmacovigilance; Regulatory Guidelines; Toxicology; Teratogenesis; Pharmacokinetics.

1. Introduction

The regulation of medicinal products for use during pregnancy constitutes a critical and sensitive domain within pharmaceutical governance. Pregnancy represents a unique physiological state where drug therapy exerts a dual impact, affecting both the maternal host and the developing fetus. Consequently, pharmaceutical agents administered in this context must adhere to exceptionally high standards of safety, efficacy, and quality. Regulatory authorities worldwide maintain specific frameworks to evaluate, approve, and monitor such medications to mitigate risks while ensuring that pregnant individuals have access to life-sustaining treatments [1].

The necessity for stringent oversight became a global priority following the Thalidomide crisis in the mid-twentieth century, which resulted in thousands of cases of phocomelia and other severe congenital malformations. This event demonstrated the catastrophic potential of inadequate drug testing and insufficient regulatory surveillance [2]. In the decades following, global systems were reinforced, mandating comprehensive preclinical reproductive toxicity studies and more rigorous clinical evaluations prior to marketing authorization.

Leading agencies, such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), now enforce robust standards for the approval of medications intended for this population. These requirements involve detailed assessments of embryo-fetal development in animal models, complex risk-benefit analyses, and structured labeling requirements [3]. A significant challenge remains the relative scarcity of human clinical trial data, as ethical considerations often lead to the exclusion of pregnant women from early-phase studies. As a result, regulatory bodies depend heavily on preclinical findings, observational data, and pharmacovigilance systems to inform their decisions [4].

* Corresponding author: Lokesh A

2. Physiological Transformations and Pharmacokinetic Implications

Pregnancy induces profound physiological shifts that directly influence the absorption, distribution, metabolism, and excretion (ADME) of pharmaceutical agents. These alterations are central to the regulatory evaluation of drug safety and the determination of appropriate dosing regimens.

2.1. Maternal Absorption

During gestation, elevated levels of progesterone result in decreased gastrointestinal motility. This leads to delayed gastric emptying and a prolonged intestinal transit time, which can significantly alter the rate and extent of drug absorption [6]. The common occurrence of nausea and vomiting, particularly during the first trimester, may reduce the bioavailability of orally administered medications. Changes in gastric pH also occur, potentially decreasing the absorption of weakly basic drugs while facilitating the uptake of weak acids. Conversely, increased blood flow to the skin and mucous membranes can enhance the absorption of medications delivered via transdermal or intramuscular routes [7].



Figure 1. Mechanisms of Maternal-Fetal Drug Transfer

2.2. Volume of Distribution and Protein Binding

The expansion of maternal plasma volume by approximately 30% to 50% significantly impacts drug distribution. Total body water and adipose tissue also increase, which dilutes the plasma concentration of hydrophilic drugs and may necessitate higher loading doses to achieve therapeutic levels [8]. Lipophilic agents may demonstrate a prolonged half-life due to increased distribution into fat stores. Simultaneously, plasma albumin concentrations typically decrease, which reduces the degree of protein binding. This results in a higher "free" or active fraction of drugs that are normally highly protein-bound, potentially increasing both therapeutic effects and the risk of maternal-fetal toxicity [9].

Table 1. Physiological Adaptations and Their Pharmacokinetic (PK) Consequences

Physiological Parameter	Gestational Change	Impact on Pharmacokinetics (PK)
Gastrointestinal Motility	Decreased (Progesterone effect)	Delayed absorption rate; altered T_{max} for oral drugs.
Gastric pH	Increased	Altered ionization; decreased absorption of weak bases.
Plasma Volume	Increased (30–50%)	Increased Volume of Distribution (Vd); diluted drug concentration.
Serum Albumin	Decreased	Increased free fraction of highly protein-bound drugs.
Hepatic CYP3A4 Activity	Induced (Increased)	Accelerated metabolism; reduced efficacy of specific substrates.
Renal Blood Flow/GFR	Increased (Up to 50%)	Enhanced clearance; requires higher doses for renally excreted drugs.

2.3. Hepatic Metabolism and Enzyme Induction

The activity of hepatic enzymes undergoes variable changes during pregnancy. Specific cytochrome P450 (CYP) enzymes, such as CYP3A4, CYP2D6, and CYP2C9, are induced, which can accelerate the metabolism of certain drugs and reduce their clinical efficacy. In contrast, other enzymes like CYP1A2 and CYP2C19 may show decreased activity, potentially leading to drug accumulation and toxicity [10]. These metabolic shifts require clinicians to perform careful dose adjustments and monitor plasma levels where possible to ensure that maternal health is maintained without exposing the fetus to excessive drug concentrations.

2.4. Renal Clearance and Elimination

One of the most significant changes in the pregnant state is the marked increase in renal blood flow and the glomerular filtration rate (GFR), which can rise by as much as 50% by the second trimester. This enhancement facilitates the rapid clearance of drugs that are primarily eliminated unchanged by the kidneys, such as certain antibiotics and lithium [11]. Regulatory assessments must account for this increased elimination rate, as standard adult doses may result in sub-therapeutic maternal concentrations, jeopardizing the treatment of acute infections or chronic conditions [12].

2.5. Impact on Dosing and Safety

The intersection of these physiological changes creates a complex landscape for safety assessment. Drug exposure affects two distinct biological entities with different sensitivities. The timing of exposure is a critical factor in risk assessment; the first trimester represents the highest risk for structural teratogenesis during the period of organogenesis, while second and third-trimester exposure may lead to functional deficits, growth restriction, or neonatal withdrawal syndromes [13].

Regulatory agencies require that pharmaceutical developers provide detailed data on placental transfer and reproductive toxicity. These assessments are not static and must be updated as post-marketing data becomes available through pregnancy registries. The goal is to move away from theoretical risk toward a data-driven model that supports precision dosing for the pregnant patient.

3. Regulatory Standards for Drug Approval and Labeling

The regulatory guidelines for medications used during pregnancy has evolved from a defensive posture of exclusion to a proactive, data-driven format. This transition aims to provide clinicians with nuanced information rather than binary "safe or unsafe" classifications.

3.1. Evolution of the FDA Labeling Standards

For several decades, the U.S. Food and Drug Administration (FDA) utilized a letter-based category system (A, B, C, D, and X) to communicate fetal risk. While these categories were intended to simplify decision-making, they often led to clinical oversimplification and misunderstanding. Category C, for instance, became a "catch-all" for drugs with insufficient human data, regardless of whether animal studies showed risk or not. This lack of granularity often resulted in either unnecessary anxiety for patients or the inadvertent use of higher-risk agents [14].



Figure 2. Regulatory Lifecycle of Maternal-Fetal Drugs

In 2015, the FDA implemented the Pregnancy and Lactation Labeling Rule (PLLR), which removed the letter categories in favor of narrative risk summaries. The PLLR requires drug manufacturers to provide detailed information under three specific subheadings: Pregnancy, Lactation, and Females and Males of Reproductive Potential.

Table 2. Comparison of FDA Legacy Categories and PLLR Narrative Components

Feature	Legacy Category System (A, B, C, D, X)	Modern PLLR System (Narrative)
Risk Communication	Single-letter grades.	Detailed narrative risk summaries.
Data Sources	Often lacked transparency on human vs. animal data.	Explicitly separates human clinical data from animal findings.
Clinical Guidance	Minimal; focused on binary "safe/unsafe."	Includes dosing, maternal risk, and fetal monitoring advice.
Lactation	Separate, brief section.	Comprehensive subsection (8.2) including drug-in-milk data.
Reproductive Potential	Not systematically addressed.	New subsection (8.3) for contraception and infertility risk.

3.1.1. The Pregnancy Subsection (8.1)

Under the PLLR, the pregnancy subsection must include a "Risk Summary" that describes the likelihood of adverse developmental outcomes based on available data. If a drug is tracked via a pregnancy exposure registry, the label must provide contact information to encourage enrollment. The "Clinical Considerations" section offers guidance on disease-associated maternal and fetal risks, dose adjustments required due to physiological changes, and potential neonatal adverse reactions [15].

3.1.2. Females and Males of Reproductive Potential (8.3)

A significant addition in the modern framework is the requirement to discuss the impact of medications on fertility and the necessity for pregnancy testing or contraception before and during treatment. This section addresses the longitudinal nature of reproductive health, recognizing that drug exposure in either parent can have implications for future gestations [16].

3.2. The Perspective of European Medicines Agency (EMA)

The European Medicines Agency (EMA) follows a similar trajectory but places a distinct emphasis on the risk-benefit balance through its Good Pharmacovigilance Practices (GVP). The EMA requires that all marketing authorization applications include a "Risk Management Plan" (RMP) that specifically addresses pregnancy. Unlike the FDA's narrative focus, the EMA guidelines often mandate proactive post-marketing studies as a condition of approval if the drug is likely to be used by women of childbearing age [17].

3.3. International Harmonization (ICH)

The International Council for Harmonisation (ICH) provides the scientific basis for these regional regulations. The ICH S5(R3) guideline is the global standard for detecting toxicity to reproduction and development. It outlines the specific animal models and study designs required to evaluate a drug's impact on fertility, embryo-fetal development, and pre- and post-natal outcomes. This harmonization ensures that preclinical data generated in one region is acceptable to regulatory bodies worldwide, streamlining the global approval process for essential medications [18].

4. Preclinical Requirements for Drug Approval

Preclinical studies serve as the primary safeguard for drugs entering the market, especially when human data is absent. These studies are designed to identify potential hazards that could manifest as structural defects, functional impairments, or pregnancy loss.

4.1. Reproductive and Developmental Toxicity Studies

Toxicological evaluation typically involves three distinct segments of study. Segment I focuses on fertility and early embryonic development, assessing the drug's impact on gamete maturation, mating behavior, and implantation. Segment II, often referred to as the teratogenicity study, examines the period of organogenesis. This segment is conducted in at least two species typically a rodent and a non-rodent (such as a rabbit) to identify potential structural malformations. Segment III addresses pre- and post-natal

development, monitoring the drug's effects from the end of organogenesis through lactation and the functional development of the offspring [19].

Table 3. ICH Standardized Preclinical Reproductive Toxicity Segments

Study Segment	Focus Area	Parameters Evaluated
Segment I	Fertility and Early Embryonic Development	Gamete maturation, mating behavior, implantation.
Segment II	Embryo-Fetal Development (Teratogenicity)	Structural malformations, visceral/skeletal defects.
Segment III	Pre- and Post-natal Development	Late pregnancy, parturition, lactation, and offspring behavior.
Genotoxicity	Mutagenicity	DNA damage and chromosomal aberrations.

4.2. Genotoxicity and Carcinogenicity Assessments

Beyond immediate developmental toxicity, medications must be screened for their potential to cause genetic damage or induce malignancy. Genotoxicity tests evaluate whether a substance can cause DNA mutations or chromosomal damage, which could lead to heritable defects or developmental failures. While carcinogenicity studies are long-term, they are crucial for medications intended for chronic use during the reproductive years [20].

5. Clinical Evaluation and Ethical Constraints

The "therapeutic orphan" status of pregnant individuals is a direct result of the ethical and legal complexities associated with clinical research in this population.

5.1. The Ethical Barriers

The historical exclusion of pregnant women from clinical trials was driven by the principle of "protection from research." However, the medical community now recognizes that this exclusion effectively results in "protection from the benefits of research." Without controlled data, clinicians are forced to prescribe drugs "off-label," essentially performing uncontrolled experiments on the pregnant population [21].

5.2. Toward Responsible Inclusion

Recent bioethical shifts advocate for the "careful inclusion" of pregnant participants when the research offers potential direct benefit to the mother or fetus, and the risk is minimized through robust preclinical data. The development of ethical research frameworks now emphasizes that pregnant women should be protected *through* research, rather than *from* research. This involves adaptive trial designs, such as enrolling pregnant women only after Phase I and II trials in non-pregnant adults have established basic safety profiles [22].

5.3. Observational Research and Pregnancy Registries

In the absence of randomized controlled trials, observational studies and pregnancy exposure registries serve as the backbone of maternal-fetal pharmacovigilance. These registries systematically collect data on women who have been exposed to specific medications during pregnancy. While they provide invaluable real-world evidence, they are often limited by selection bias and the difficulty of tracking long-term neurodevelopmental outcomes beyond infancy [23].

6. Risk-Benefit Assessment and Clinical Decision-Making

The clinical application of pharmaceutical agents during pregnancy is governed by a rigorous risk-benefit assessment. This process is not merely a calculation of toxicity but a comparative evaluation of the dangers of untreated maternal disease versus the potential for drug-induced fetal harm.

6.1. Balancing Maternal Health and Fetal Protection

Untreated chronic conditions, such as epilepsy, hypertension, and diabetes, pose significant risks to both the mother and the fetus. For instance, uncontrolled maternal seizures can lead to fetal hypoxia or physical trauma, while untreated hypertension increases the risk of preeclampsia and placental abruption. In these scenarios, the therapeutic benefit of maintaining maternal stability often

outweighs the theoretical or documented risks associated with drug exposure. Regulatory guidance emphasizes that the "risk of not treating" must be a primary component of the clinical summary provided in drug labeling [24].

Table 4. Clinical Management of Common Gestational Conditions

Clinical Condition	Preferred Therapeutic Agents	Regulatory/Clinical Considerations
Hypertension	Labetalol, Methyldopa, Nifedipine	Avoid ACE inhibitors/ARBs due to fetal renal toxicity.
Diabetes	Insulin, Metformin	Glycemic control is vital to prevent macrosomia.
Anticoagulation	Low Molecular Weight Heparin (LMWH)	Preferred over Warfarin (which crosses the placenta).
Bacterial Infection	Penicillins, Cephalosporins	High renal clearance in 3rd trimester may require dose increase.
Epilepsy	Lamotrigine, Levetiracetam	Use monotherapy at lowest effective dose; monitor levels.

6.2. Trimester-Specific Considerations

The timing of drug administration is a critical determinant of outcome. Risk-benefit ratios fluctuate throughout the gestational period. While structural teratogenesis is the primary concern during the first trimester, medications administered in the third trimester are evaluated for their potential to cause functional toxicity, such as neonatal respiratory depression or premature closure of the ductus arteriosus. Modern labeling systems facilitate this by providing trimester-specific data where available, allowing for more precise clinical timing of therapy [25].

7. Adverse Drug Reactions and Pharmacovigilance

Adverse drug reactions (ADRs) in the context of pregnancy are multi-generational. They encompass maternal toxicities, immediate fetal harm, neonatal syndromes, and delayed developmental effects that may not manifest for years.

7.1. Classification of Reproductive Toxicities

Fetal ADRs are generally categorized into structural, functional, and developmental domains. Teratogenic effects involve the disruption of organogenesis, leading to physical malformations. Fetotoxic effects refer to physiological damage occurring after the organs have formed, such as renal impairment or growth restriction. Neonatal ADRs include withdrawal syndromes or "floppy infant syndrome" resulting from exposure near the time of delivery. A particularly challenging category is delayed developmental toxicity, where prenatal exposure leads to long-term cognitive or behavioral impairments that are difficult to link to a specific drug without large-scale longitudinal data [26].



Figure 3. Classification of Adverse Drug Reactions (ADRs) in Pregnancy

7.2. The Role of Active Pharmacovigilance

Because traditional clinical trials are often underpowered to detect rare birth defects, post-marketing surveillance is the primary tool for signal detection. Active pharmacovigilance involves the systematic monitoring of pregnancy outcomes in women exposed to new molecular entities. Regulatory authorities utilize databases such as the FDA Adverse Event Reporting System (FAERS) and EudraVigilance to identify emerging safety signals. The transition from passive reporting to active, registry-based surveillance is essential for the timely update of safety information and the prevention of widespread exposure to unidentified teratogens [27].

8. Contraindicated Medications and High-Risk Agents

Certain medications are classified as having a risk that clearly outweighs any potential therapeutic benefit, often leading to absolute contraindications or highly restricted distribution programs.

8.1. Potent Teratogens and Restricted Access

Drugs like isotretinoin and thalidomide are subject to stringent Risk Evaluation and Mitigation Strategies (REMS) or similar global programs. These protocols mandate pregnancy testing, the use of multiple contraceptive methods, and patient education to ensure zero exposure during gestation. Other high-risk categories include certain anticonvulsants (e.g., valproic acid), which are associated with significant neural tube defects, and ACE inhibitors, which can cause severe fetal renal dysfunction if used in the second or third trimesters [28].

Table 5. Established Teratogens and Associated Developmental Risks

Agent/Class	Primary Risk Period	Documented Developmental Outcomes
Isotretinoin	1st Trimester	Craniofacial, cardiac, and CNS malformations.
Thalidomide	1st Trimester (Days 20–36)	Phocomelia (limb reduction), internal organ defects.
Valproic Acid	1st Trimester	Neural tube defects (e.g., Spina Bifida), cognitive delay.
Warfarin	1st Trimester	Fetal Warfarin Syndrome (nasal hypoplasia, stippled epiphyses).
ACE Inhibitors	2nd and 3rd Trimester	Fetal hypotension, renal anuria, skull hypoplasia.
Tetracyclines	2nd and 3rd Trimester	Permanent tooth discoloration and bone growth inhibition.

8.2. Therapeutic Alternatives

Regulatory frameworks encourage the identification of safer alternatives within the same therapeutic class. For example, while warfarin is contraindicated due to its potential for fetal bleeding and skeletal defects, heparin derivatives are recommended as safer anticoagulants because they do not cross the placental barrier. Providing these comparative safety profiles in drug documentation is a key requirement of modern labeling standards [29].

9. Current Trends

9.1. Advanced Preclinical Models

The development of "placenta-on-a-chip" technology represents a significant leap in predicting drug behavior. These microfluidic devices use human cells to simulate the complex interface of the placental barrier, allowing researchers to measure drug transfer rates and cellular responses with higher accuracy than animal models. Additionally, 3D organoids derived from stem cells can be used to study the impact of drugs on specific fetal tissues, such as the developing brain or heart, providing a non-invasive way to screen for developmental toxicity [30].

9.2. Physiologically Based Pharmacokinetic (PBPK) Modeling

Computational modeling is becoming an essential tool for dose optimization. PBPK models utilize maternal physiological data such as cardiac output and renal clearance to predict drug concentrations in both maternal and fetal compartments. These models can simulate various dosing scenarios across different trimesters, allowing for the development of individualized treatment plans that maintain efficacy while minimizing exposure.

9.3. Precision Medicine and Pharmacogenomics

Inclusion of pharmacogenomic data in regulatory assessments may soon allow for the identification of individuals at higher risk for ADRs or those who require specific dose adjustments. Variations in maternal drug-metabolizing enzymes and placental transporters can significantly influence fetal exposure. The medical community can move toward a "precision pregnancy" model by tailoring therapy based on genetic profiles that optimizes outcomes for the most sensitive populations [31].



Figure 4. Techniques for Enhancing Maternal-Fetal Safety

10. Conclusion

The regulation of medications for use during pregnancy remains a complex and evolving challenge that bridges the gap between maternal clinical needs and fetal protection. Modern regulatory frameworks have transitioned from legacy letter-based risk categories toward a more nuanced, narrative-based system, such as the FDA's Pregnancy and Lactation Labeling Rule (PLLR). This shift empowers healthcare providers with detailed clinical considerations and evidence-based risk summaries, facilitating informed shared decision-making. Despite these advancements, the inherent "evidence gap" caused by the ethical exclusion of pregnant individuals from clinical trials continues to necessitate a heavy reliance on animal data and post-marketing surveillance. Strengthening global harmonization through the International Council for Harmonisation (ICH) and expanding the reach of pregnancy exposure registries are vital steps toward identifying rare or delayed adverse outcomes. The combination of innovative biotechnologies, such as placenta-on-a-chip models and physiologically based pharmacokinetic (PBPK) modeling, offers a promising path toward precision medicine in pregnancy. The medical community can ensure that maternal health is maintained without compromising neonatal development by optimizing therapeutic efficacy while minimizing teratogenic risks. Ultimately, a proactive, multi-disciplinary approach combining rigorous regulation, ethical research expansion, and active pharmacovigilance is essential to advance the safety and efficacy of maternal-fetal therapeutics.

References

[1] Feghali M, Venkataramanan R, Caritis S. Pharmacokinetics of drugs in pregnancy. Seminars in Perinatology. 2015;39(7):512-519.

[2] Vargesson N. Thalidomide-induced teratogenesis: History and mechanisms of action. Birth Defects Research Part C: Embryo Today: Reviews. 2015;105(2):140-156.

[3] Sahin L, Mahoney J, Abernathy K, et al. The Pregnancy and Lactation Labeling Rule: The FDA's new rule on drug labeling. Obstetrical & Gynecological Survey. 2016;71(1):49-55.

[4] Lyerly AD, Little MO, Faden R. The THRIFT study: Thinking about research in individuals who are pregnant. The American Journal of Bioethics. 2011;11(5):1-3.

[5] Broussard CS, Rasmussen SA, Reefhuis J, et al. Maternal treatment with opioid analgesics and risk for birth defects. American Journal of Obstetrics and Gynecology. 2011;204(4):314.e1-314.e11.

[6] Costantine MM. Physiologic and pharmacokinetic changes in pregnancy. Frontiers in Pharmacology. 2014;5:65.

[7] Pariente G, Leibson T, Carls A, et al. Pregnancy-associated changes in pharmacokinetics: A systematic review. PLoS Medicine. 2016;13(11):e1002160.

[8] Frederick RK, Briggs GG. Drugs in Pregnancy and Lactation: A Reference Guide to Fetal and Neonatal Risk. 11th ed. Philadelphia: Wolters Kluwer; 2017.

[9] Koren G, Nordeng H. Counseling pregnant women about drug safety: Practical guidance for clinicians. Canadian Family Physician. 2012;58(3):317-321.

[10] Jeong H. Alterations in drug-metabolizing enzymes during pregnancy: Mechanisms and clinical implications. Drug Metabolism Reviews. 2010;42(2):331-344.

[11] Hebert MF, Easterling TR, Kirby B, et al. Effects of pregnancy on CYP3A and P-glycoprotein activities as measured by disposition of midazolam and digoxin: A University of Washington Obstetric-Fetal Pharmacology Research Unit study. Clinical Pharmacology & Therapeutics. 2008;84(2):248-253.

[12] Mitchell AA, Gilboa SM, Werler MM, et al. Medication use during pregnancy, with particular focus on prescription drugs: 1976–2008. American Journal of Obstetrics and Gynecology. 2011;205(1):51.e1-51.e8.

[13] Andrade SE, Gurwitz JH, Davis RL, et al. Prescription drug use in pregnancy. American Journal of Obstetrics and Gynecology. 2004;191(2):398-407.

[14] Pernia S, DeMaio FG. Using the FDA Pregnancy Categories to advise patients: A study of pharmacy residents. Journal of Pharmacy Practice. 2014;27(2):154-157.

[15] U.S. Food and Drug Administration. Content and format of labeling for human prescription drug and biological products; requirements for pregnancy and lactation labeling. Federal Register. 2014;79(233):72063-72103.

[16] Ramoz LL, Patel-Shori NM. Recent changes in pregnancy and lactation labeling: Review of women's health. Clinical Therapeutics. 2014;36(11):1735-1744.

[17] European Medicines Agency. Guideline on the exposure to medicinal products during pregnancy: Need for post-authorisation data. London: EMA; 2005. Report No.: EMEA/CHMP/313666/2005.

[18] International Council for Harmonisation. ICH S5(R3) detection of toxicity to reproduction for human pharmaceuticals. Geneva: ICH; 2020.

[19] Bailey GP. Reproductive toxicity. In: Faqi AS, editor. A Comprehensive Guide to Toxicology in Nonclinical Drug Development. 2nd ed. London: Academic Press; 2017. p. 437-471.

[20] Brent RL. Environmental causes of human congenital malformations: The pediatrician's role in dealing with these problems. Pediatrics. 2004;113(Supplement 3):957-968.

[21] Little MO, Lyerly AD, Faden RR. Ethical issues in mental health research with pregnant women. In: Goldkind SF, Sahin L, Huo D, editors. Ethical and Regulatory Aspects of Clinical Research. Baltimore: Johns Hopkins University Press; 2012.

[22] van der Graaf R, van der Zande IS, den Ruijter HM, et al. Fair inclusion of pregnant women in clinical trials: An integrated strategy. Trials. 2018;19(1):1-10.

[23] Gils C, Broe A, Damkier P. Pregnancy exposure registries: A review of methodology and data quality. Therapeutic Advances in Drug Safety. 2022;13:20420986221115167.

[24] Schaefer C, Peters P, Miller RK. Drugs During Pregnancy and Lactation: Treatment Options and Risk Assessment. 3rd ed. London: Academic Press; 2015.

[25] Nordeng H, Koren G. Counseling pregnant women about drug safety: Practical guidance for clinicians. Canadian Family Physician. 2012;58(3):317-321.

[26] Polifka JE, Friedman JM. Teratogenic mechanisms. Annual Review of Pharmacology and Toxicology. 2002;42(1):299-322.

[27] Moore TJ, Ahmad SR, Furberg CD. Adverse drug reaction reporting by patients: An analysis of fifty-four sources. Health Policy. 1994;30(1-3):199-231.

[28] Slone D, Siskind V, Heinonen OP, et al. Antenatal exposure to the phenothiazines in relation to congenital malformations, perinatal mortality rate, birth weight, and intelligence quotient score. American Journal of Obstetrics and Gynecology. 1977;128(5):486-488.

[29] Bates SM, Greer IA, Middeldorp S, et al. VTE, thrombophilia, antithrombotic therapy, and pregnancy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):e691S-e736S.

[30] Blundell C, Tess ER, Schanzer AS, et al. A microphysiological model of the human placental barrier. Lab on a Chip. 2016;16(16):3065-3073.

[31] Zhang ZY, Shuster J, Baker SD, et al. Pharmacogenomics in pregnancy. Clinical Pharmacology & Therapeutics. 2014;95(4):375-377.